Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical images

Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning

David W. Cescon and David N. Juurlink
CMAJ January 20, 2009 180 (2) 251; DOI: https://doi.org/10.1503/cmaj.080727
David W. Cescon BSc MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David N. Juurlink MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A 54-year-old woman was brought to hospital from an apartment fire. She had altered mental status, hypotension and evidence of inhalational injury, but no burns. Her carboxyhemoglobin level was 29%, and her lactate level was 16 mmol/L. She was treated with supplemental and hyperbaric oxygen for carbon monoxide intoxication. Hydroxocobalamin 5 g was administered intravenously in the intensive care unit for presumed cyanide poisoning. Subsequently, the patient's skin (Figure 1A) and urine (Figure 1B) became bright red.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1: Photographs showing bright red discoloration of the patient's skin (A) and urine (B) after treatment with hydroxocobalamin for cyanide poisoning.

Cyanide poisoning often occurs in victims of smoke inhalation. Tests that can confirm a diagnosis of cyanide poisoning are rarely available. However, treatment should not be delayed. The diagnosis is clinical and characterized by altered mental status, cardiovascular instability and lactic acidosis. Hydroxocobalamin has been approved recently as a therapy for cyanide poisoning. It is relatively safe and is better tolerated than the ingredients of the traditional cyanide antidote kit (amyl nitrite, sodium nitrite and sodium thiosulfate). The nitrites induce methemoglobinemia, which can worsen hypotension and reduce the oxygen content of the blood, an important consideration in patients with concomitant carbon monoxide poisoning. Hydroxocobalamin should be administered as soon as cyanide poisoning is suspected — ideally in the prehospital setting.1 By combining with cyanide, hydroxocobalamin forms cyanocobalamin (vitamin B12), restoring mitochondrial function.2 Hydroxocobalamin imparts a harmless and transient reddish colour to the skin and urine. It may also cause transient hypertension, which can be beneficial in patients with cyanide poisoning.1

Footnotes

  • Clinical images are chosen because they are particularly intriguing, classic or dramatic. Submissions of clear, appropriately labelled high-resolution images must be accompanied by a figure caption and the patient's written consent for publication. A brief explanation (300 words maximum) of the educational significance of the images with minimal references is required.

REFERENCES

  1. 1.↵
    Borron SW, Baud FJ, Barriot P, et al. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med 2007;49:794-801, 801.e1-2.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Shepherd G, Velez LI. Role of hydroxocobalamin in acute cyanide poisoning. Ann Pharmacother 2008;42:661-9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 180 (2)
CMAJ
Vol. 180, Issue 2
20 Jan 2009
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning
David W. Cescon, David N. Juurlink
CMAJ Jan 2009, 180 (2) 251; DOI: 10.1503/cmaj.080727

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning
David W. Cescon, David N. Juurlink
CMAJ Jan 2009, 180 (2) 251; DOI: 10.1503/cmaj.080727
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Antidotes for toxicological emergencies: A practical review
  • Google Scholar

More in this TOC Section

  • Subungual malignant melanoma
  • Diffuse panbronchiolitis
  • Tension gastrothorax: a life-threatening cause of acute abdominal pain
Show more Clinical Images

Similar Articles

Collections

  • Topics
    • Emergency medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire